{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T04:11:55Z","timestamp":1745554315911,"version":"3.40.4"},"reference-count":4,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[2001]]},"abstract":"The in vitro activities of quinupristin\/dalfopristin (Synercid), ampicillin, erythromycin, clarithromycin, vancomycin, teicoplanin, ciprofloxacin and tetracycline were examined and compared against 526 gram-positive bacteria. The minimal inhibitory concentrations (MICs) for quinupristin\/dalfopristin against <i>Staphylococcus aureus,<\/i> including methicillin-resistant strains, were low (MIC<sub>90<\/sub> = 0.5 mg\/l), and were comparable with those of vancomycin and teicoplanin. This compound was superior to the macrolides and highly active against <i>Streptococcus pneumoniae<\/i> (both penicillin-sensitive and penicillin-resistant strains), with MIC<sub>90<\/sub> = 2 mg\/l. It was also active against other streptococci, with MIC<sub>90<\/sub> = 4 mg\/l. However, this agent is less active against enterococci (MIC<sub>90<\/sub> = 32 mg\/l). Quinupristin\/dalfopristin showed high activity against gram-positive anaerobes, including <i>Clostridium<\/i> spp., <i>Peptococcus<\/i> spp. and <i>Peptostreptococcus<\/i> spp., with MIC<sub>90<\/sub> \u22642 mg\/l. Quinupristin\/dalfopristin was also investigated for its post-antibiotic effect (PAE) and bactericidal kinetics against nine strains of gram-positive organisms, including staphylococci, enterococci and pneumococci. Exponentially growing (log phase) cultures were exposed to quinupristin\/dalfopristin at 2 \u00d7 MIC. Growth kinetics was evaluated using viable counting. The drug was uniformly bactericidal against pneumococci and staphylococci within 2 and 8 h of exposure, respectively. The killing activity against enterococci was weak; there was little or no reduction in bacterial count over 24 h of incubation. PAEs ranging from 2.13 to 3.28 h, 0.92 to 3.02 h and 1.89 to 7.07 h were produced on the tested pneumococci, staphylococci and enterococci, respectively. This study showed that quinupristin\/dalfopristin is a promising agent active against gram-positive bacteria. The prolonged PAEs also suggest that the drug could be used intermittently at more widely spaced dosing intervals against gram-positive organisms.<\/jats:p>","DOI":"10.1159\/000048530","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T13:07:10Z","timestamp":1050412030000},"page":"243-249","source":"Crossref","is-referenced-by-count":5,"title":["In vitro Activity and Post-Antibiotic Effect of Quinupristin\/Dalfopristin (Synercid)"],"prefix":"10.1159","volume":"47","author":[{"given":"Thomas K.W.","family":"Ling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kitty S.C.","family":"Fung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augustine F.B.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2001,5,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1097(00)00463-8"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(93)90113-L"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)80002-3"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.1059-1061.2000"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/48530","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/48530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:04:42Z","timestamp":1745467482000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000048530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001]]},"references-count":4,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2001,8,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000048530","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"type":"print","value":"0009-3157"},{"type":"electronic","value":"1421-9794"}],"subject":[],"published":{"date-parts":[[2001]]}}}